



201 Technology Drive • Irvine • California • 92618  
Telephone: (949) 450-5400  
Facsimile: (949) 450-5300  
Email: IR@endocare.com  
Website: [www.endocare.com](http://www.endocare.com)

FOR RELEASE May 24, 2007 at 6:00 am EDT

Investor Contact:

Matt Clawson  
Allen & Caron, Inc.  
(949) 474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)

Media Contact:

Len Hall  
Allen & Caron, Inc.  
(949) 474-4300  
[len@allencaron.com](mailto:len@allencaron.com)

For Additional Information:

Craig T. Davenport, CEO  
Michael R. Rodriguez, CFO  
Endocare, Inc.  
(949) 450-5400

**ENDOCARE TO PRESENT AT THE FRIEDMAN, BILLINGS, RAMSEY 2007 GROWTH CONFERENCE**

IRVINE, CA (May 24, 2007) . . . Endocare, Inc. (OTC BB: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced that it is scheduled to make an investor presentation at the Friedman, Billings, Ramsey 2007 Growth Conference at 8:15 a.m. ET on Thursday, May 31, 2007. The conference will be held at the Grand Hyatt New York Hotel, May 30 & 31.

A live webcast of the Company's presentation at the conference will be available via a link provided at [www.endocare.com/investors/webcasts.php](http://www.endocare.com/investors/webcasts.php). An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days.

**About Endocare**

Endocare, Inc. ([www.endocare.com](http://www.endocare.com)) is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###